296 related articles for article (PubMed ID: 23837641)
21. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
[TBL] [Abstract][Full Text] [Related]
22. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
[TBL] [Abstract][Full Text] [Related]
23. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.
Yeh JM; Lowry KP; Schechter CB; Diller LR; Alagoz O; Armstrong GT; Hampton JM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Oeffinger KC; Trentham-Dietz A; Stout NK
Ann Intern Med; 2020 Sep; 173(5):331-341. PubMed ID: 32628531
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
Walsh EM; Farrell MP; Nolan C; Gallagher F; Clarke R; McCaffrey JA; Kennedy MJ; Barry M; Kell MR; Gallagher DJ
Ir J Med Sci; 2016 Feb; 185(1):189-94. PubMed ID: 25673166
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making.
Long EF; Ganz PA
JAMA Oncol; 2015 Dec; 1(9):1217-8. PubMed ID: 26335890
[No Abstract] [Full Text] [Related]
26. Breast MRI screening for average-risk women: A monte carlo simulation cost-benefit analysis.
Mango VL; Goel A; Mema E; Kwak E; Ha R
J Magn Reson Imaging; 2019 Jun; 49(7):e216-e221. PubMed ID: 30632645
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue.
Geuzinge HA; Bakker MF; Heijnsdijk EAM; van Ravesteyn NT; Veldhuis WB; Pijnappel RM; de Lange SV; Emaus MJ; Mann RM; Monninkhof EM; de Koekkoek-Doll PK; van Gils CH; de Koning HJ;
J Natl Cancer Inst; 2021 Nov; 113(11):1476-1483. PubMed ID: 34585249
[TBL] [Abstract][Full Text] [Related]
28. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
29. Total cost-effectiveness of mammography screening strategies.
Mittmann N; Stout NK; Lee P; Tosteson AN; Trentham-Dietz A; Alagoz O; Yaffe MJ
Health Rep; 2015 Dec; 26(12):16-25. PubMed ID: 26676235
[TBL] [Abstract][Full Text] [Related]
30. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
31. [Cost-effectiveness of multiple screening modalities on breast cancer in Chinese women from Shanghai].
Wu F; Mo M; Qin XX; Fang H; Zhao GM; Liu GY; Chen YY; Cao ZG; Yan YJ; Lyu LL; Xu WH; Shao ZM
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Dec; 38(12):1665-1671. PubMed ID: 29294584
[No Abstract] [Full Text] [Related]
32. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.
Robertson C; Arcot Ragupathy SK; Boachie C; Dixon JM; Fraser C; Hernández R; Heys S; Jack W; Kerr GR; Lawrence G; MacLennan G; Maxwell A; McGregor J; Mowatt G; Pinder S; Ternent L; Thomas RE; Vale L; Wilson R; Zhu S; Gilbert FJ
Health Technol Assess; 2011 Sep; 15(34):v-vi, 1-322. PubMed ID: 21951942
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women.
Taneja C; Edelsberg J; Weycker D; Guo A; Oster G; Weinreb J
J Am Coll Radiol; 2009 Mar; 6(3):171-9. PubMed ID: 19248993
[TBL] [Abstract][Full Text] [Related]
34. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.
Tina Shih YC; Dong W; Xu Y; Shen Y
Value Health; 2019 Feb; 22(2):185-193. PubMed ID: 30711063
[TBL] [Abstract][Full Text] [Related]
35. Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.
Obdeijn IM; Heijnsdijk EA; Hunink MG; Tilanus-Linthorst MM; de Koning HJ
Eur J Cancer; 2016 Aug; 63():135-42. PubMed ID: 27318001
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations.
Lipton JH; Zargar M; Warner E; Greenblatt EE; Lee E; Chan KKW; Wong WWL
Hum Reprod; 2020 Feb; 35(2):434-445. PubMed ID: 32099994
[TBL] [Abstract][Full Text] [Related]
37. Telemammography for breast cancer screening: a cost-effective approach in Argentina.
Malek Pascha VA; Sun L; Gilardino R; Legood R
BMJ Health Care Inform; 2021 Jul; 28(1):. PubMed ID: 34281995
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
Lee JM; Kopans DB; McMahon PM; Halpern EF; Ryan PD; Weinstein MC; Gazelle GS
Radiology; 2008 Mar; 246(3):763-71. PubMed ID: 18309013
[TBL] [Abstract][Full Text] [Related]
39. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in
Guindalini RSC; Zheng Y; Abe H; Whitaker K; Yoshimatsu TF; Walsh T; Schacht D; Kulkarni K; Sheth D; Verp MS; Bradbury AR; Churpek J; Obeid E; Mueller J; Khramtsova G; Liu F; Raoul A; Cao H; Romero IL; Hong S; Livingston R; Jaskowiak N; Wang X; Debiasi M; Pritchard CC; King MC; Karczmar G; Newstead GM; Huo D; Olopade OI
Clin Cancer Res; 2019 Mar; 25(6):1786-1794. PubMed ID: 30154229
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
